Thus, targeting of the BMP4–GREM1/2 axis in patients suffering from cardiac inflammation offers protection of cardiomyocyte integrity, reduction of cardiac fibrosis and, thereby, prevention of heart failure. This evidence concerns the gene GREM1 and heart failure.